-
Happy to see a great collaboration and project, having fruitful results just published in Cancers MDPI.
BreastCaRANKL has been a 4-year project, aiming at the development of an innovative model of RANKL-induced breastcancer and the establishment of a preclinical platform for drug evaluation. Moreover, it has been the meeting point for a great internal collaboration,... -
On the way to Boston for the Targeted Radiopharmaceuticals Summit-US.
BIOEMTECH Laboratories, COO Maritina G. Rouchota and CSO Theodoros Karampelas are participating in this great event, starting tomorrow. We are looking forward to getting updated on the new trends for radiopharmaceuticals, theragnostics and targeted therapy and meeting new people. Visit our booth to meet our team and come to... -
Moments from BIOEMTECH summer party.
It is nice to see the team growing even more! -
One more gamma-eye installation is now happening somewhere in central Europe.
OK, perhaps installation is not the best word to describe the 3-minute process to set up gamma-eye and start acquiring data. Looking forward to seeing the first images and share some photos of Sofia Lagoumtzi and our collaborators! -
Meet BIOEMTECH eye at SNMMI 2023 in Chicago
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual conference takes place in Chicago, and it is a great opportunity to meet and discuss about “eyes”, our unique technology that makes possible imaging of all dyes and isotopes,... -
BIOEMTECH was present at the 3rd Hellenic Biocluster (HBio) Forum
Interesting discussions on global biotech innovation and bridging the gap between research and commercialization, inspiring sessions on clinical research, investment opportunities, and fruitful networking! Many thanks for the wonderful event, Ioanna Koukli and Stamatiki Kritas! -
BIOEMTECH Laboratories are officially GLP accredited!
We are very happy to receive the official Good Laboratory Practice accreditation, regarding our preclinical toxicology studies. Preclinical toxicology studies are a crucial part in drug development, evaluating the safety and potential toxicity of a drug candidate, at a stage before it is tested in human clinical trials. During this step, potential side... -
BIOEMTECH was present at Thessaloniki for Beyond Expo 2023
BIOEMTECH participated in the panel discussion “A 360 view on startup challenges, ” which Metavallon VC partner George Karantonis moderated by Metavallon VC partner George Karantonis and featuring us, Cogitat, technologies, and Klisto. It was nice to discuss... -
Eliza Lambidis, Ph.D. will represent BIOEMTECH in the 25th iSRS in Honoloulou
Only a few days are left for the 25th International Symposium on Radiopharmaceutical Sciences that takes place in Honolulu, Hawaii. Our R&D Radiopharmaceutical Chemist, Dr. Eliza Lambidis will be there, presenting the poster P-128 “A Preclinical Platform to Thoroughly... -
First images of γ-eye showing Cu-67 antibody imaging on a lung oncology model
Cu-67 can fully be supported by our BIOEMTECH gamma-eye as shown through a recent study conducted in our laboratories for preclinical research purposes. Following non-invasive in vivo imaging for 6 consecutive days, tumor targeting can be quantified, and the...